论文部分内容阅读
目的探讨低分子量肝素联合氯吡格雷治疗不稳定性心绞痛(UAP)的临床疗效及安全性。方法选择诊断明确的不稳定性心绞痛患者60例,随机分为治疗组(30例)和对照组(30例)。对照组采用阿司匹林及其他抗心绞痛药物,治疗组在以上治疗基础上加用低分子量肝素钙皮下注射,氯吡格雷口服。结果治疗组能明显减少心绞痛发作频率(P<0.05),改善临床症状,对改善缺血性ST段压低明显优于对照组(P<0.05),且对凝血指标影响不大(P>0.05)。结论在常规治疗心绞痛基础上加用低分子量肝素联合氯吡格雷对UAP更有效,而且安全。
Objective To investigate the clinical efficacy and safety of low molecular weight heparin combined with clopidogrel in the treatment of unstable angina pectoris (UAP). Methods Sixty patients with diagnosed unstable angina pectoris were randomly divided into treatment group (30 cases) and control group (30 cases). Control group, aspirin and other anti-angina drugs, the treatment group in addition to the above treatment with low molecular weight heparin calcium subcutaneous injection of clopidogrel orally. Results The treatment group can significantly reduce the frequency of angina pectoris (P <0.05), improve clinical symptoms, and improve the ischemic ST segment depression significantly better than the control group (P <0.05), and has little effect on the coagulation index (P> 0.05) . Conclusion The combination of low molecular weight heparin with clopidogrel on the basis of conventional angina pectoris is more effective and safe for UAP.